Rapid Micro Biosystems, Inc. (RPID) Tops Q2 EPS by 1c, beats revenue, provides guidance

Rapid Micro Biosystems, Inc. (NASDAQ: RPID) reported Q2 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $5 million versus the consensus estimate of $4.15 million.

Full Year 2023 Outlook:

The Company is reaffirming its prior full year 2023 outlook for revenue of at least $22.0 million, representing growth of approximately 30%, and the placement of at least 15 systems.

For earnings history and earnings-related data on Rapid Micro Biosystems, Inc. (RPID) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results